CLINICAL EFFICIENCY AND ANTI-INFLAMMATORY ACTIVITYOF THERAPY IN CHILDREN WITH PERENNIAL ALLERGICRHINITIS



Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

Background. Intranasal corticosteroids and nonsedating antihistamines are the drug classes most often prescribed
to treat allergic rhinitis (AR). Treatment guidelines recommend a combination of these agents for moderate to severe AR. Objective: To compare the efficacy of mometasone furoate (MF) nasal spray plus desloratadine (DL)
with that of monotherapy with the individual agents in 6-16 years old patients with perennial AR.
Methods. A prospective, randomized, open label, parallel group study of the efficiency of MF nasal spray plus DL and of monotherapy with MF or DL in children with persistent allergic rhinitis aged 6-16 in a 12week period
was conducted. The efficacy of therapy was evaluated by level of markers of an allergic inflammation, indicators
of a bronchial hyperresponsiveness and by dynamics of clinical symptoms.
Results. Combined therapy (DL+MF) restores balance of cytokines: increase the Тh1 activity and decrease the Т2 activity. Combined therapy found to be effective in the majority of AR patients.
Сnclusion. Combined therapy with MF and DL in the treatment of perennial AR in children has clinical advan60

About the authors

V I Petrov

Volgograd State Medical University

Volgograd State Medical University

N V Maljuzhinskaya

Volgograd State Medical University

Volgograd State Medical University

I N Shishimorov

Volgograd State Medical University

Email: ivan_shishimorov@mail.ru
Volgograd State Medical University

A V Razvalyaeva

Volgograd State Medical University

Volgograd State Medical University

References

  1. Bousquet J., Reid J., van Weel C. et al. Allergic rhinitis management pocket reference 2008. Allergy. 2008, v. 63, p. 990-996.
  2. Гущин И.С., Ильина Н.И., Польнер С.А. Аллергический ринит: Пособие для врачей. «ГНЦ Институт иммунологии». РААКИ. М., 2002, 68 с.
  3. Горячкина Л.А., Ненашева Н.М. Взаимосвязь ринита и астмы: терапевтическая значимость интраназальных кортикостероидов. Рос. аллергол. журн. 2009, № 1, с. 60-64.
  4. Allergic Rhinitis and its Impact on Asthma (ARIA) 2008 Update. Allergy (Suppl. 86). 2008, v. 63, p. 1-160.
  5. Canonica G.W., Complati E. Minimal persistent inflammation in allergiс rhinitis: implications for current treatment strategies. Clin. Exp. Immunol. 2009, v. 158, p. 260-271.
  6. Valdesoiro L., Bosque M., Marco M.T. et al. Allergic rhinitis and bronchial hyperreactivity. Allergol. Immunopathol. (Madr.). 2004, v. 32, p. 340-343.
  7. Cirillo I., Pistorio A., Tosca M., Ciprandi G. Impact of allergic rhinitis on asthma: effects on bronchial hyperreactivity. Allergy. 2009, v. 64, p. 439-444.
  8. Sin B.A., Yildiz O.A., Dursun A.B. et al. Airway hyperresponsiveness: a comparative study of methacholine and exercise challenges in seasonal allergic rhinitis with or without asthma.J. Asthma. 2009, v. 46, p. 486-491.
  9. Braunstahl G.J., Hellings P.W. Nasobronhial interactionmechanism in allergic airways disease. Curr. Opin. Otolaryngol. Heat. Neck. Surg. 2006, v. 14, p. 176-182.
  10. Braunstahl G.J., Kleinjan A., Overbeek S.E. et al. Segmental bronchial provocation induces nasalinflammationin allergicrhinitis patients. Am. J. Respir. Crit. Care. Med. 2000, v. 161 (6), p. 2051-2057.
  11. Agrawal D.K. Anti-inflammatory properties of desloratadine. Clin. Exp. Allergy. 2004, v. 34, p. 1342-1348.
  12. Bryce P.J., Geha R., Oettgen H.C. Desloratadine inhibits allergen-induced airway inflammation and bronchial hyperresponsiveness and alters T-cell responses in murine models of asthma. J. Allergy Clin. Immunol. 2003, v. 112, p. 149-158.
  13. Schroeder J.T., Schleimer R.P., Lichtenstein L.M., Kreutner W. Inhibition of cytokine generation and mediator release by human basophils treated with desloratadine. Clin. Exp. Allergy. 2001, v. 31, p. 1369-1377.
  14. Lippert U., Moller A., Welker P., Artuc M., Henz B.M. Inhibition of cytokine secretion from human leukemic mast cells and basophils by H1- and H2-receptor antagonists. Exp. Dermatol. 2000, v. 9, p. 118-124.
  15. Papi A., Papadopoulos N.G., Stanciu L.A. et al. Effect of desloratadine and loratadine on rhinovirus-induced intercellular adhesion molecule 1 upregulation and promoter activation in respiratory epithelial cells. J. Allergy Clin. Immunol. 2001, v. 108, p. 221-228.
  16. Canonica G.W., Tarantini F., Compalati E., Penagos M. Efficacy of desloratadine in the treatment of allergic rhinitis: a meta-analysis of randomized, double-blind, controlled trials. Allergy. 2007, v. 62, p. 359-366.
  17. Ciprandi G., Cirillo I., Vizzaccaro A. et al. Desloratadine and levocetirizine improve nasal symptoms, airflow, and allergic inflammation in patients with perennial allergic rhinitis: a pilot study. Int. Immunopharmacol. 2005, v. 5, p. 1800-1808.
  18. Хаитов Р.М., Ильина Н.И., Латышева Т.В. Рациональная фармакотерапия аллергических заболеваний. М., 2007, 502 с.
  19. Zhou J., Liu D.-F., Liu C. et al. Glucocorticods inhibit degranulation of mast cells in allergic asthma via nongenomic mechanism. Allergy. 2008, v. 63 (9), p. 1177-1185.
  20. Hafez S.F., Sallam M.M., Ibraheem S.A. Local expression of IL-4 and IL-5 in perennial allergic rhinitis and their modulation by topical corticosteroid therapy. Egypt. J. Immunol. 2004, v. 11, p. 111-121.
  21. Magari M., Ikeda M., Asakura M. et al. Suppressive effects of mometasone furoate on an antigen-specific IgE antibody response and production of IL-4 in mice. Immunopharmacol. Immunotoxicol. 2006, v. 28, p. 491-500.
  22. Chapman R.W., Sehring S.J., Garlisi C.G. et al. Anti-inflammatory activity of inhaled mometasone furoate in allergic mice. Arzneimittelforschung. 1998, v. 48, p. 384-391.
  23. Lumry W.R. A review of the preclinical and clinical data of newer intranasal steroids used in the treatment of allergic rhinitis.J. Allergy Clin. Immunol. 1999, v. 104, p. 150-158.
  24. Frieri M., Therattil J., Chavarria V. et al. Effect of mometasone furoate on early and late phase inflammation in patients with seasonal allergic rhinitis. Ann. Allergy Asthma Immunol. 1998, v. 81, p. 431-437.
  25. Anolik R. Mometasone Furoate Nasal Spray With Loratadine Study Group Clinical benefits of combination treatment with mometasone furoate nasal spray and loratadine vs monotherapy with mometasone furoate in the treatment of seasonal allergic rhinitis. Ann. Allergy Asthma Immunol. 2008, v. 100, p. 264-271.
  26. Pinar E., Eryigit O., Oncel S. et al. Efficacy of nasal corticosteroids alone or combined with antihistamines or montelukast in treatment of allergic rhinitis. Auris. Nasus. Larynx. 2008, v. 35, p. 61-66.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright © Pharmarus Print Media, 1970



This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies